Edwards, St. Jude Pursue Opposite Pricing Strategies For New Tissue Valves
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical does not expect a significant price premium for its BioCor and Epic porcine tissue heart valves upon U.S. approval, anticipated in 2004 and 2006, respectively, the firm says